Large gap with delayed quotes
|
Last quote
01/06/2025 -
17:31:17
|
Bid
01/06/2025 -
17:19:23
|
Bid Volume |
Ask
01/06/2025 -
17:19:58
|
Ask Volume |
|---|---|---|---|---|
|
42.45
+0.95
(
+2.29% )
|
42.55
|
1,012 |
42.70
|
197 |
Analysis date: 03.01.2025
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 27.12.2024.
Interest
Very weak
Very weak
Very weak interest since 27.12.2024.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 22.11.2024 at a price of 41.30.
Evaluation
Overvalued
Overvalued
Based on its growth potential and our own criteria, at its current price the stock is moderately overvalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this (since 29.10.2024), the stock traded below its moving average. The confirmed Technical Reverse (Tech Reverse + 1.75%) point is
4wk Rel Perf
2.89%
2.89%
The four week relative overperformance versus STOXX600 is 2.89%.
Sensibility
Middle
Middle
Moderate, no change over 1 year.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 1.80%.
Mkt Cap in $bn
0.55
0.55
With a market capitalization <$2bn, BASILEA PHARMACEUTIC is considered a small-cap stock.
G/PE Ratio
0.18
0.18
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
13.04
13.04
The estimated PE is for the year 2026.
LT Growth
2.31%
2.31%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
4
4
Over the last seven weeks, an average of 4 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
99
99
For 1% of index variation, the stock varies on average by 0.99%.
Correlation
0.31
0.31
Stock movements are strongly independent of index variations.
Value at Risk
9.96
9.96
The value at risk is estimated at CHF 9.96. The risk is therefore 24.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
12.11.2004
12.11.2004